Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Liabilities and Shareholders Equity: 2010-2025

Historic Liabilities and Shareholders Equity for Altimmune (ALT) over the last 15 years, with Sep 2025 value amounting to $218.4 million.

  • Altimmune's Liabilities and Shareholders Equity rose 47.74% to $218.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $705.4 million, marking a year-over-year decrease of 2.06%. This contributed to the annual value of $139.3 million for FY2024, which is 33.87% down from last year.
  • According to the latest figures from Q3 2025, Altimmune's Liabilities and Shareholders Equity is $218.4 million, which was up 14.76% from $190.3 million recorded in Q2 2025.
  • Altimmune's 5-year Liabilities and Shareholders Equity high stood at $264.3 million for Q1 2021, and its period low was $139.3 million during Q4 2024.
  • In the last 3 years, Altimmune's Liabilities and Shareholders Equity had a median value of $183.3 million in 2023 and averaged $178.4 million.
  • As far as peak fluctuations go, Altimmune's Liabilities and Shareholders Equity spiked by 387.25% in 2021, and later slumped by 33.87% in 2024.
  • Over the past 5 years, Altimmune's Liabilities and Shareholders Equity (Quarterly) stood at $218.9 million in 2021, then declined by 5.45% to $206.9 million in 2022, then climbed by 1.79% to $210.6 million in 2023, then tumbled by 33.87% to $139.3 million in 2024, then surged by 47.74% to $218.4 million in 2025.
  • Its last three reported values are $218.4 million in Q3 2025, $190.3 million for Q2 2025, and $157.3 million during Q1 2025.